Abstract
A total of 66 skin biopsies from persons with Alzheimer's disease (AD) or Down's syndrome (DS) and from persons without AD were used in this study. The age range was from 7 to 89 years. Positive immunoreactivity of skin biopsies to monoclonal antibody 4G8, which is reactive to amino acid residue 17–24 of synthetic amyloid β protein (Aβ), and 4G8-Fab (the antigen-binding fragment of 4G8 IgG, reactive only to amyloid plaque) was observed in the epidermis-dermis junction or the basement membrane of the epidermis and in some blood vessels of the biopsy skins of 13/18 (72%) AD, 9/10 (90%) DS, and 14/38 (37%) non-AD control cases. The Fisher exact probability test revealed a significant difference (P=0.0415 one-tailed) in immunoreactivity between AD and age-matched controls. There was also a significant difference (P=0.0152 one-tailed; P=0.0200 two-tailed) between DS and age-matched control in the same test. Immuno-gold electron microscopy examination of these cases with positive immunoreactivity revealed that the gold particles were deposited along the basement membrane of the epidermis. Amyloid fibrils were not observed in the regions with gold particles. Results of this study suggest that Aβ is associated with the basement membrane of skin and is present in amorphous, non-fibrillar form as soluble Aβ.
Similar content being viewed by others
References
Askanas V, Engel WK, Alvarez RB (1992) Light and electron microscopic localization of β-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 141: 31–36
Bugiani O, Giaccone G, Verga L, Pollo B, Ghetti B, Frangione B, Tagliani F (1990) Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neurosci Lett 119: 56–59
Cai XD, Golde TE, Younkin SG (1993) Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514–516
Cotman CW, Pike CJ, Copani A (1992) β-amyloid neurotoxicity: a discussion of in vitro findings. Neurobiol Aging 13: 587–590
Giaccone G, Tagliavini F, Linoli G, Bouras C, Frigerio L, Frangione B, Bugiani O (1989) Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 97: 232–238
Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG (1992) Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255: 728–730
Haass C, Schlossmacher MG, Hung AY, Vigo-Pelffrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359: 322–324
Haltia M, Ghiso J, Prelli F, Gallo G, Kiuru S, Sommer H, Palo J, Frangione B (1990) Amyloid in familial amyloidosis. Finnish type is antigenically and structurally related to Gelsolin. Am J Pathol 136: 1223–1228
Haltia M, Prelli F, Ghiso J, Kiuru S, Sommer H, Palo J, Frangione B (1990) Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsolin, an actin-binding protein. Biochem Biophys Res Commun 167: 927–932
Husby G, Araki S, Benditt EP, Benson MD, Cohen AS, Frangione B, Glenner GG, Natvig JB, Westermark P (1991) The 1990 guidelines for nomenclature and classification of amyloid and amyloidosis. In: Natvig JB, et al (eds) Amyloid and Amyloidodid 1990. Kluwer Academic Publishers, Dordrecht, pp 7–11
Joachim CL, Mori H, Selkoe DJ (1989) Amyloid β-protein deposition in tissue other than brain in Alzheimer's disease. Nature 341: 226–230
Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza V, Hong H, Wisniewski HM (1990) Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci Res Commun 7: 113–122
Kowall NW, McKee AC, Yankner BA, Beal MF (1992) In vivo neurotoxicity of β-amyloid [β(1–40)] and the β(25–35) fragment. Neurobiol Aging 13: 537–542
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ARDRA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939–944
Mehta PD, Kim KS, Wisniewski HM (1991) ELISA as a laboratory test to aid the diagnosis of Alzheimer's Disease. Tech Diagn Pathol 2: 99–112
Selkoe D, Mori H, Joachim C (1990) Extracerebral deposition of β-amyloid protein (βAP) in Alzheimer's disease (abstract). J Neuropathol Exp Neurol 49: 3307
Seubert P, Vigo-Pelfrey C, Each F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D (1992) Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359: 325–327
Soininen H, Syrjanen S, Heinonen O, Neittaanmaki H, Paljarvi L, Reikkinen PJ, Syrjanen K, Beyreuther K (1992) Detection of β/A4-peptide in skin biopsy in Alzheimer's disease (abstract). Neurology 42: 359
Tagliavini F, Giaccone G, Frangione B, Bugiani O (1988) Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett 93: 191–196
Tagliavini F, Giaccone G, Bugiani O, Frangione B (1993) Ubiquitinated neurites are associated with preamyloid and cerebral amyloid β deposits in patients with hereditary cerebral hemorrhage with amyloidosis Dutch type. Acta Neuropathol 85: 267–271
Wisniewski HM, Wegiel J (1992) The role of perivascular and microglial cells in fibrillogenesis of β-protein amyloid and PrP protein in Alzheimer's disease and scrapie. Res Immunol 143: 642–643
Wisniewski HM, Wen GY, Kim KS (1989) Comparison of four staining methods on detection of neuritic plaques. Acta Neuropathol 78: 22–27
Wisniewski HM, Wen GY, Kim KS (1989) Immunoreactivity of Fab of monoclonal antibodies to amyloid β-peptide (abstract). J Neuropathol Exp Neurol 48: 352
Wisniewski HM, Mehta PD, Kim KS, Merz GS (1989) Cerebrospinal fluid-based laboratory test for Alzheimer disease. In: Bolier F, et al (eds) Biological markers of Alzheimer disease. Springer-Verlag, Berlin Heidelberg New York Tokyo, pp 23–29
Wisniewski HM, Wegiel J, Wang KC, Lach B (1992) Ultrastructural studies of the cells forming amyloid in the cortical vessel walls in Alzheimer's disease. Acta Neuropathol 84: 117–127
Wisniewski T, Ghiso J, Frangione B (1991) Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun 179: 1247–1254
Wisniewski T, Ghiso J, Frangione B (1994) Alzheimer's disease and soluble Aβ. Neurobiol Aging 15: 143–152
Author information
Authors and Affiliations
Additional information
Supported in part by funds from the New York State Office of Mental Retardation and Developmental Disabilities and grant nos. PO1-AGO-4220 and PO1-AG11531 from the National Institute on Aging, NIH and the fund for the center for trace metal studies and environmental neurotoxicology
Rights and permissions
About this article
Cite this article
Wen, G.Y., Wisniewski, H.M., Blondal, H. et al. Presence of non-fibrillar amyloid β protein in skin biopsies of Alzheimer's disease (AD), Down's syndrome and non-AD normal persons. Acta Neuropathol 88, 201–206 (1994). https://doi.org/10.1007/BF00293394
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00293394